ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

patritumab deruxtecan

Also written as “HER3-DXd”, “Patritumab deruxtecan” and “Patritumab Deruxtecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Esophageal Neoplasms · Neoplasms · Gastrointestinal Neoplasms, led by 2 companies.

Drug pagePatritumab deruxtecan: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 2, 202517 company-led studies, 15 open or runningCo-development: Daiichi Sankyo and Merck, Oct 2023Next primary completion: May 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck99 open or runningphase 3since Jul 2, 2025Nov 14, 2019May 9, 2028phase 2 · NCT06445972
Daiichi Sankyoits history only86 open or runningphase 3since Apr 15, 2022Nov 28, 2016Nov 19, 2030phase 2 · NCT06172478
  • Named in Merck’s own pipeline as patritumab deruxtecan (MK-1022), phase 3, as of Nov 2, 2026 (source).

Also a collaborator on its studies: AstraZeneca.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2019Named patritumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 121
  2. Nov 14, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04165070 · 450 planned · United States, Canada, Hungary and more
  3. Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
  4. May 31, 2024Phase 2 study in Esophageal NeoplasmsNCT06445972 · 210 planned · United States, Brazil, Chile and more
  5. Jun 17, 2024Phase 2 study in Esophageal NeoplasmsNCT06469944 · 160 planned · United States, Brazil, Chile and more
  6. Sep 11, 2024Phase 2 study in Gastrointestinal NeoplasmsNCT06596694 · 180 enrolled · United States, Australia, Canada and more
  7. Nov 11, 2024Phase 2 study in Breast NeoplasmsNCT06686394 · 181 planned · United States, Canada, Israel and more
  8. Dec 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06731907 · 90 planned · United States, Chile, Greece and more
  9. Jan 21, 2025Phase 2 study in Breast NeoplasmsNCT06797635 · 372 planned · United States, South Korea, Spain and more
  10. Feb 27, 2025Phase 2 study in NeoplasmsNCT06941272 · 50 planned · United States, Australia, Belgium and more
  11. Jul 2, 2025Phase 3 study in Breast NeoplasmsNCT07060807 · 1,000 planned · United States, Argentina, Australia and more
  12. Oct 21, 2026Primary completion moved from 2030-04-18 to 2032-08-02Date moved laterphase 2 · +27 months · NCT06686394

Ahead

  1. May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsNCT06445972
  2. Dec 7, 2028Primary completion: phase 2 study in Gastrointestinal NeoplasmsNCT06596694
  3. Sep 12, 2029Primary completion: phase 2 study in Esophageal NeoplasmsNCT06469944
  4. Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsNCT06797635

TargetBeta

“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activit…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),”NCIt, by rule
“Receptor tyrosine-protein kinase erbB-3 binding agent”ChEMBL 37, by rule

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
beruzatatug pelitecanruleMediLink Therapeutics (Suzhou)phase 39
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 9 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07060807Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJul 14, 20331,000
NCT06941272Neoplasms · United States, Australia, Belgium and more2RecruitingDec 30, 203050
NCT06797635Breast Neoplasms · United States, South Korea, Spain and more2RecruitingDec 31, 2029372
NCT06731907Carcinoma, Non-Small-Cell Lung · United States, Chile, Greece and more2RecruitingMar 12, 203290
NCT06686394Breast Neoplasms · United States, Canada, Israel and more2RecruitingAug 2, 2032181
NCT06596694Gastrointestinal Neoplasms · United States, Australia, Canada and more2Active, not recruitingDec 7, 2028180
NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingSep 12, 2029160
NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMay 9, 2028210
NCT04165070Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more2RecruitingFeb 13, 2032450

How it is read

Names in the registry

  • “HER3-DXd”, 8 entries
  • “Patritumab deruxtecan”, 5 entries
  • “Patritumab Deruxtecan”, 5 entries
  • “Patritumab Deruxtecan (Fixed dose)”, 1 entry
  • “Patritumab Deruxtecan (Up-Titration)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.